We’d love to hear your feedback on this activity. It helps us to continually improve our products.
In Part Two of this video interview, Prof Nicholas Short (The University of Texas MD Anderson Cancer Center, Houston, TX, USA) summaries the rationale, design and eligibility criteria of his phase II trial looking at ponatinib and blinatumomab for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia, and summarizes the key take-home conclusions. A total of […]
Professor Jorge Cortes (Georgia Cancer Center, Augusta, GA, USA) summarizes three more important abstracts, the first two from the 27th Congress of the European Hematology Association (EHA) looking at combination therapies with ruxolitinib, a JAK2 inhibitor. The third abstract was presented at the 2022 American Society of Clinical Oncology (ASCO) annual meeting, looking at rusfertide […]
Professor Jorge Cortes (Georgia Cancer Center, Augusta, GA, USA) summarizes two more important abstracts from the 27th Congress of the European Hematology Association (EHA) looking at magrolimab, an antibody blocking CD47, “don’t eat me” signal on cancer cells. The first is a phase III trial (NCT05079230) assessing magrolimab in combination with venetoclax and azacitidine in […]
Professor Jorge Cortes (Georgia Cancer Center, Augusta, GA, USA) summarizes one of his main highlights from the 27th Congress of the European Hematology Association (EHA). The phase III QuANTUM-First trial (NCT02668653) assessed quizartinib in relapsed/refractory FLT3–internal tandem duplication positive acute myeloid leukemia. The primary endpoint of the study was overall survival and this showed that […]
Professor Jorge Cortes (Georgia Cancer Center, Augusta, GA, USA) shares the long-term efficacy and safety data from the 96-week update of the ASCEMBL trial of asciminib with a novel mechanism of action in patients with Philadelphia chromosome-positive chronic myeloid leukaemia chronic phase. The abstract ‘Efficacy and safety results from ASCEMBL, a phase 3 study of […]
Prof Barbara Eichhorst (University Hospital Cologne, Cologne, Germany) discusses the impact of venetoclax plus obinutuzumab on the treatment of patients with chronic lymphocytic leukaemia (CLL) who are unfit for chemoimmunotherapy. The abstract ‘TIME-LIMITED VENETOCLAX-OBINUTUZUMAB +/- IBRUTINIB IS SUPERIOR TO CHEMOIMMUNOTHERAPY IN FRONTLINE CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): PFS CO-PRIMARY ENDPOINT OF THE RANDOMIZED PHASE 3 GAIA/CLL13 […]
Prof. John Marshall (Ruesch Center for the Cure of Gastrointestinal Cancer, and, Georgetown University Hospital, Washington, DC, USA) joins us to discuss the major highlights neuroendocrine cancers presented at ASCO 2022. Prof. Marshall discusses new findings from the ECOG-ACRIN E2211 trial, which showed the longest progression-free survival and highest response rates with temozolomide plus capecitabine […]
Prof. John Marshall (Ruesch Center for the Cure of Gastrointestinal Cancer, and, Georgetown University Hospital, Washington, DC, USA) joins us to discuss the major highlights in upper gastrointestinal cancers. Prof. Marshall highlights the K-UMBRELLA study, a biomarker-integrated trial for second-line treatment of advanced gastric cancer (0:33); randomized phase 2 trial of the AIO (2:46); and […]
Dr Catherine Shu (Columbia University Irving Medical Center, New York, NY, USA) discusses the findings of the CHRYSALIS-2 study, which supports the use of amivantamab in certain groups of patients with advanced non-small-cell lung cancer (NSCLC) and represents a chemotherapy-free regimen. The abstract ‘Amivantamab and lazertinib in patients with EGFR-mutant non–small cell lung (NSCLC) after […]
Get the latest clinical insights from touchONCOLOGY